Caplin Point Laboratories regulatory approval announcements

Every Caplin Point Laboratories regulatory approval announcement on NSE and BSE, newest first, each with its own page.

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements

14 May 2026 19:00 IST BSE

Regulatory Approval Caplin Point Laboratories Ltd CAPLIPOINT

Caplin Point Laboratories Regulatory Approval

Caplin Point's subsidiary secured USFDA approval for Foscarnet Sodium Injection. The generic drug addresses a US market with approximately ₹142.5 Crore in annual sales.

Value: ₹142.5 Cr

Open announcement → Read the filing ↗

5 May 2026 12:34 IST BSE

Regulatory Approval Caplin Point Laboratories Ltd CAPLIPOINTAlfa Alert

Caplin Point Laboratories Regulatory Approval

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received final USFDA approval for its Calcium Gluconate Injection USP. The product addresses acute symptomatic hypocalcemia and targets a US market with annual sales of approximately ₹674.5 Crore ($71 million). This approval strengthens the company's injectable portfolio in the regulated US market.

Value: ₹674.5 Cr

Open announcement → Read the filing ↗